LOGIN  |  REGISTER
Amneal Pharmaceuticals
Chimerix

Syra Health Secures $660,000 Population Health Contract Extension

March 13, 2025 | Last Trade: US$0.22 0.04 19.09

CARMEL, Ind., March 13, 2025 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today a one-year, $660,000 Population Health contract extension with a national healthcare organization. This agreement, combined with the previous year's agreement, brings the total contract value up to $1.32 million.

"We are pleased to continue securing valuable population health contract extensions, as demonstrated by this announcement," said Dr. Deepika Vuppalanchi, Chair and CEO of Syra Health. "This is a testament to the trust our partners place in us and highlights our ongoing ability to deliver impactful healthcare solutions that improve health outcomes. As we continue to secure such extensions, we are confident in our strategy to deliver long-term growth, expanded reach, and sustainable value creation."

Through the contract extension, Syra Health's team will continue providing Healthcare Effectiveness Data and Information Set (HEDIS®) outreach and support services. This extension enables Syra Health to further contribute to the organization's efforts to improve healthcare quality, enhance member outcomes, and reduce costs through expert data analysis and member outreach initiatives, as initially announced in March of 2024.

This contract extension supports the continued expansion of Syra Health's Population Health business unit, which is one of the key growth contributors to the company's diversifying revenue base. The success and renewal of these contracts align with Syra Health's strategic focus of strengthening its revenue streams through higher-margin business segments.

About Syra Health

Syra Health is a healthcare technology company powering better health in critical areas such as behavioral and mental health, population health, and the healthcare workforce. The company's leading-edge technology products and innovative services focus on prevention, access, and affordability. With a commitment to improving health, Syra Health is advancing healthcare solutions nationwide and around the world. For more information, please visit www.syrahealth.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy, and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts

For Media Inquiries:
Christine Drury
Corporate Communications Director
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.

For Investor Inquiries:
Corbin Woodhull
Managing Director, Global Advisory
Hayden IR
602-476-1821
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page